Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey
| dc.contributor.author | Canonica G Walter | |
| dc.contributor.author | Klimek Ludger | |
| dc.contributor.author | Acaster Sarah | |
| dc.contributor.author | Dollner Ralph | |
| dc.contributor.author | Kaulsay Ranbir | |
| dc.contributor.author | Lo Siu Hing | |
| dc.contributor.author | Price David B | |
| dc.contributor.author | Scadding Glenis K | |
| dc.contributor.author | Valovirta Erkka | |
| dc.contributor.author | Zieglmayer Petra | |
| dc.contributor.organization | fi=kliininen laitos|en=Department of Clinical Medicine| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.61334543354 | |
| dc.converis.publication-id | 56055729 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/56055729 | |
| dc.date.accessioned | 2022-10-28T13:46:30Z | |
| dc.date.available | 2022-10-28T13:46:30Z | |
| dc.description.abstract | <p><strong>Objective</strong><br></p><p><strong></strong>The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients' lives and (3) explore factors associated with treatment satisfaction.<br></p><p><strong>Methods</strong><br></p><p><strong></strong>A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March-June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM-9; max score = 100). Participants (aged >= 18 years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.<br></p><p><strong>Results</strong><br></p><p>Pre-MP-AzeFlu treatment, participants (n = 1004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of participants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and >= 70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.<br></p><p><strong>Conclusions</strong><br></p><p>The impact of AR on patients' lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.<br></p> | |
| dc.format.pagerange | 1259 | |
| dc.format.pagerange | 1272 | |
| dc.identifier.eissn | 1473-4877 | |
| dc.identifier.jour-issn | 0300-7995 | |
| dc.identifier.olddbid | 184230 | |
| dc.identifier.oldhandle | 10024/167324 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/44263 | |
| dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/03007995.2021.1911973 | |
| dc.identifier.urn | URN:NBN:fi-fe2021093048770 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Valovirta, Erkka | |
| dc.okm.discipline | 3111 Biomedicine | en_GB |
| dc.okm.discipline | 3121 Internal medicine | en_GB |
| dc.okm.discipline | 3111 Biolääketieteet | fi_FI |
| dc.okm.discipline | 3121 Sisätaudit | fi_FI |
| dc.okm.internationalcopublication | international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | A1 ScientificArticle | |
| dc.publisher | TAYLOR & FRANCIS LTD | |
| dc.publisher.country | United Kingdom | en_GB |
| dc.publisher.country | Britannia | fi_FI |
| dc.publisher.country-code | GB | |
| dc.relation.doi | 10.1080/03007995.2021.1911973 | |
| dc.relation.ispartofjournal | Current Medical Research and Opinion | |
| dc.relation.issue | 7 | |
| dc.relation.volume | 37 | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/167324 | |
| dc.title | Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey | |
| dc.year.issued | 2021 |
Tiedostot
1 - 1 / 1
Ladataan...
- Name:
- Burden of allergic rhinitis and impact of MP AzeFlu from the patient perspective pan European patient survey.pdf
- Size:
- 2.44 MB
- Format:
- Adobe Portable Document Format
- Description:
- Publisher's version